Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SYNH | Class A Common Stock | Award | $0 | +1.32 K | +3.73% | $0.00 | 36.8 K | Mar 2, 2022 | Direct | F1 |
holding | SYNH | Class A Common Stock | 10.8 K | Mar 2, 2022 | By spouse |
Id | Content |
---|---|
F1 | Represents performance restricted stock units that were earned based upon performance criteria for the year ended December 31, 2021 and will vest in full once the Compensation and Management Development Committee of the Board of Directors of Syneos Health, Inc. determines the attainment level of the performance goals for the year ended December 31, 2023, subject to continued employment. |
Chief Development Officer & Global Head Clinical Development Solutions